NASHVILLE, Tenn. & WILMINGTON, Del.--(BUSINESS WIRE)-- <\/p>\n
Sarah Cannon Research Institute (SCRI) and AstraZeneca (AZ) announced today a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds. Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy. <\/p>\n
Through our research, we know how vital and impactful individualized treatment options are for patients battling this complex disease, said Dee Anna Smith, chief executive officer of SCRI. By partnering with AstraZeneca, we are expanding opportunities to accelerate drug development and deliver more targeted therapies to patients who urgently need them. <\/p>\n
Under the agreement, SCRI will work with AstraZeneca to identify potential patients for clinical trials and help explore biomarkers that predict response to specific treatments. In addition, SCRIs enhanced relationship with AstraZeneca will provide clinical program development leadership, medical expertise and oversight, and operational contract research organization (CRO) trial management for early phase clinical development of multiple oncology compounds. <\/p>\n
Building upon this unique collaboration with SCRI allows us to continue honing our capabilities to deliver high quality research in a timely and cost-effective manner, said Vice President of Early Clinical Development for AstraZeneca, Professor Andrew Hughes. Through this cutting-edge program design, we can rapidly and effectively implement clinical trials with greater access to a network of cancer patients for enrollment. <\/p>\n
AstraZeneca is one of the initial participants in SCRIs molecular profiling program, which is part of Sarah Cannons broader personalized medicine initiative across the United States and United Kingdom. SCRI and AstraZeneca originally entered into an agreement to develop novel oncology compounds in 2010. <\/p>\n
About Sarah Cannon Research Institute <\/p>\n
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit us onsarahcannonresearch.com. <\/p>\n
About AstraZeneca <\/p>\n
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http:\/\/www.astrazeneca.com<\/a>. <\/p>\n <\/p>\n See the original post here:<\/p>\n Sarah Cannon Research Institute And AstraZeneca Announce Personalized Medicine Partnership and Enhanced Strategic ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" NASHVILLE, Tenn. & WILMINGTON, Del.--(BUSINESS WIRE)-- Sarah Cannon Research Institute (SCRI) and AstraZeneca (AZ) announced today a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds. Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy. Continue reading